

Condensed Consolidated Interim Financial Statements of

# KWESST MICRO SYSTEMS INC.

Three and six months ended March 31, 2023, and 2022 (Unaudited – Expressed in Canadian dollars)

# Table of contents for the three and six months ended March 31, 2023, and 2022

	Page
FINANCIAL STATEMENTS	8
Condensed Consolidated Interim Statements of Financial Position	3
Condensed Consolidated Interim Statements of Net Loss and Comprehensive Loss	4
Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Deficit)	5
Condensed Consolidated Interim Statements of Cash Flows	6
Notes to the Condensed Consolidated Interim Financial Statements	7-24

# $Condensed\ Consolidated\ Interim\ Statements\ of\ Financial\ Position$

At March 31, 2023 and September 30, 2022

(Unaudited)

(		March 31,	September 30,
In Canadian dollars	Notes	2023	2022
ASSETS			
Cash and cash equivalents		\$ 3,983,691	\$ 170,545
Restricted short-term investment		30,000	30,000
Trade and other receivables	5	212,520	171,882
Inventories	6	872,520	393,538
Prepaid expenses and other		1,507,668	122,166
Deferred share offering costs		-	628,262
Current assets		6,606,399	1,516,393
Property and equipment		816,116	832,481
Right-of-use assets		179,089	208,131
Deposit		42,869	23,604
Intangible assets	7	5,192,014	4,742,854
Non-current assets		6,230,088	5,807,070
Total Assets		\$ 12,836,487	\$ 7,323,463
LIABILITIES AND SHAREHOLDERS' EQUITY			
Liabilities			
Accounts payable and accrued liabilities	8 and 9	\$ 1,499,653	\$ 4,459,481
Accrued royalties liability		- , , , , , , , , , , , , , , , , , , ,	150,000
Lease obligations		72,681	69,150
Borrowings	10	-,	2,199,978
Contract liabilities	11	267,272	47,271
Warrant liabilities	12 and 13(b)	2,591,996	-
Current liabilities		4,431,602	6,925,880
Accrued royalties liability		1,203,112	1,115,207
Lease obligations		169,226	206,471
Borrowings	10	109,220	78,796
	10	1 252 229	
Non-current liabilities Total Liabilities		1,372,338 5,803,940	1,400,474 8,326,354
Total Liabilities		3,003,740	6,320,334
Shareholders' Equity (Deficit)			
Share capital	13(a)	30,943,174	19,496,640
Warrants	13(b)	2,089,388	1,959,796
Contributed surplus	13(c)	3,424,644	3,551,330
Accumulated other comprehensive loss	13(0)	(79,994)	(101,418)
Accumulated deficit		(29,344,665)	(25,909,239)
Total Shareholders' Equity (Deficit)		7,032,547	(1,002,891)
Zame, (Denote)		.,502,017	(-,- 0=,0)1)
Total Liabilities and Shareholders' Equity (Deficit)		\$ 12,836,487	\$ 7,323,463
San Nata 2(a) Caina announ and Nata 10 Commitments			-

See Note 2(a) Going concern and Note 19 Commitments and contingencies.

See accompanying notes to the unaudited condensed consolidated interim financial statements.

On behalf of the Board of Directors:

(signed) John McCoach, Director

(signed) David Luxton, Director

# Condensed Consolidated Interim Statements of Net Loss and Comprehensive Loss Three and six months ended March 31, 2023 and 2022

(Unaudited)

-		T 15		C! 35 (I	G' M d
		Three Months Ended	Three Months Ended	Six Months Ended	Six Months Ended
		March 31,	March 31,	March 31,	March 31,
In Canadian dollars	Notes	2023	2022	2023	2022
In Canadian dollars	110168	2023	2022	2023	2022
Revenue	15	\$ 161,403	\$ 166,251	\$ 478,736	\$ 183,716
Cost of sales	13	(128,634)	(142,012)	(268,218)	(167,491)
Gross profit		32,769	24,239	210,518	16,225
Operating expenses					
General and administrative		1,665,971	1,033,017	2,644,458	2,088,157
Selling and marketing		1,152,916	733,364	1,607,103	2,079,755
Research and development, net		306,680	465,344	569,509	1,259,756
Total operating expenses		3,125,567	2,231,725	4,821,070	5,427,668
Operating loss		(3,092,798)	(2,207,486)	(4,610,552)	(5,411,443)
Other income (expenses)					
Share issuance recovery (costs)		57,548	_	(1,309,545)	_
Net finance costs	16	(11,107)	(72,479)	(554,684)	(120,121)
Foreign exchange loss		(19,684)	(9,044)	(150,040)	(299)
Loss on disposals		-	(1,165)	-	(1,165)
Change in fair value of warrant liabilities	12	1,838,972	-	3,189,395	-
Total other income (expenses), net		1,865,729	(82,688)	1,175,126	(121,585)
Net loss		\$ (1,227,069)	\$ (2,290,174)	\$ (3,435,426)	\$ (5,533,028)
Other comprehensive income:		, , , ,		, (,, ,, ,	,
-					
Items that are or may be reclassified subsequently to profit or loss:					
Foreign currency translation differences		3,442	11,653	21,424	15,039
		,	\$ (2,278,521)	,	\$ (5,517,989)
Total comprehensive loss		\$ (1,223,627)	\$ (2,270,321)	\$ (3,414,002)	\$ (3,317,989)
Net loss per share					
Basic and diluted		\$ (0.29)	\$ (3.21)	\$ (1.17)	\$ (7.83)
Weighted average number of shares outstanding					
Basic and diluted	14	4,271,594	712,401	2,925,729	706,291
	-	-,,	,	-,0,9	,—

See accompanying notes to the unaudited condensed consolidated interim financial statements.

KWESST MICRO SYSTEMS INC. Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Deficit)

Six months ended March 31, 2023, and 2022

(Unaudited)

In Canadian dollars								Total
			Contingent		Contributed	Translation		Shareholders'
	Notes	Share capital	shares	Warrants	surplus	reserve	Deficit	<b>Equity (Deficit)</b>
Balance, September 30, 2021		\$ 17,215,068	\$ -	\$ 1,848,389	\$ 2,458,211	\$ (8,991)	\$ (15,388,949)	\$ 6,123,728
Shares issued to settle debt		19,000	-	-	-	-	-	19,000
Shares and warrants issued on acquisition	4	377,503	83,319	132,000	-	-	-	592,822
Warrants exercised		237,136	-	(61,136)	-	-	-	176,000
Share-based compensation	13(c)	-	-	-	1,350,461	-	-	1,350,461
Shares for vested RSUs and PSUs		148,137	-	-	(148,137)	-	-	-
Vested RSUs and PSUs repurchased for								
withholding taxes		-	-	-	(22,815)	-	-	(22,815)
Shares issued for unsecured loans		365,888	-	-	-	-	-	365,888
Share offering costs		(26,323)	-	-	-	-	-	(26,323)
Other comprehensive income		-	-	-	-	15,039	-	15,039
Net loss		-	-	-	-	-	(5,533,028)	(5,533,028)
Balance, March 31, 2022		\$ 18,336,409	\$ 83,319	\$ 1,919,253	\$ 3,637,720	\$ 6,048	\$ (20,921,977)	\$ 3,060,772
Balance, September 30, 2022		\$ 19,496,640	\$ -	\$ 1,959,796	\$ 3,551,330	\$ (101,418)	\$ (25,909,239)	\$ (1,002,891)
Shares issued for public offering	13(a)	13,675,120	-	-	-	-	-	13,675,120
Share offering costs	13(a)	(3,050,278)	-	189,592	125,086	-	-	(2,735,600)
Shares issued for debt	13(a)	233,485	-	-	-	-	-	233,485
Warrants exercised	13(b) and 18	60,000	-	(60,000)	-	-	-	-
Share-based compensation	13(c)	-	-	-	277,047	-	-	277,047
Shares for vested RSUs and PSUs	18	528,207	-	-	(528,207)	-	-	-
Vested RSUs and PSUs repurchased for								
withholding taxes		-	-	-	(612)	-	-	(612)
Other comprehensive income		-	-	-	-	21,424	-	21,424
Net loss		-	_	_	-	-	(3,435,426)	(3,435,426)
Balance, March 31, 2023		\$ 30,943,174	\$ -	\$ 2,089,388	\$ 3,424,644	\$ (79,994)	\$ (29,344,665)	\$ 7,032,547

See accompanying notes to the unaudited condensed consolidated interim financial statements.

# ${\bf Condensed\ Consolidated\ Interim\ Statements\ of\ Cash\ Flows}$

Six months ended March 31, 2023, and 2022

(Unaudited)

		Six months	Six months
		ended	ended
In Canadian dollars	Notes	March 31, 2023	March 31, 2022
ODED ATTING A CTIN WINES			
OPERATING ACTIVITIES		Ø (2.425.426)	Φ (5.533.030)
Net loss		\$ (3,435,426)	\$ (5,533,028)
Items not affecting cash:			
Depreciation and amortization		323,878	145,186
Share-based compensation	13(c)	277,047	1,350,461
Change in fair value of warrant liabilities (including related			
foreign exchange gain)	12	(3,223,574)	-
Net finance costs	16	554,684	120,121
Loss on disposals		-	1,165
Changes in non-cash working capital items	18	(3,534,350)	1,051,854
Interest paid		(117,553)	(16,085)
Cash used in operating activities		(9,155,294)	(2,880,326)
INVESTING ACTIVITIES			
Additions of property and equipment		(136,917)	(118,703)
Investments in intangible assets	7	(598,525)	(441,074)
Deposit for advanced royalties		(148,410)	-
Recognition of open orders from acquisition	7	-	64,233
Cash acquired on acquisition	4	-	162,547
Cash flows used in investing activities		(883,852)	(332,997)
FINANCING ACTIVITIES	12( )	16.246.760	
Proceeds from U.S. IPO and Canadian Offering, net	13(a)	16,346,768	- (26.222)
Payments of share offering costs	13(a) and 18	(125,397)	(26,323)
Proceeds from borrowings	10	-	2,000,000
Payments of deferred financing fees		-	(74,055)
Repayment of borrowings		(2,333,315)	-
Repayments of lease obligations		(35,152)	(10,427)
Proceeds from exercise of warrants		-	176,000
Proceeds from exercise of stock options		-	-
Repurchase of vested RSUs and PSUs for withholding taxes		(612)	(22,815)
Cash flows provided by financing activities		13,852,292	2,042,380
Net change in cash during the period		3,813,146	(1,170,943)
Cash, beginning of period		170,545	2,688,105
Cash, end of period		\$ 3,983,691	\$ 1,517,162
Cash and cash equivalents consist of the following:			
Cash held in banks		953,741	1,517,162
Short-term guaranteed investment certificates		3,029,950	1,517,102
Cash and cash equivalents		3,983,691	1,517,162
Cash and cash equivalents		3,703,071	1,317,102

See Note 18 Supplemental cash flow information.

See accompanying notes to the unaudited condensed consolidated interim financial statements.

Notes to Unaudited Condensed Consolidated Interim Financial Statements Three and six months ended March 31, 2023, and 2022 (Expressed in Canadian dollars, except share amounts)

#### 1. Corporate information

#### a) Corporate information

KWESST Micro Systems Inc. (the "Company", "KWESST", "we", "our", and "us") was incorporated on November 28, 2017, under the laws of the Province of British Columbia. Our registered office is located at 550 Burrard Street, Suite 2900, Vancouver, British Columbia, Canada and our corporate office is located at Unit 1, 155 Terrence Matthews Crescent, Ottawa, Ontario, Canada. We have representative offices in the following foreign locations: Washington DC (United States), London (United Kingdom), and Abu Dhabi (United Arab Emirates).

We develop and commercialize next-generation technology solutions that deliver a tactical advantage for military, public safety agencies and personal defense markets. Our core mission is to protect and save lives.

KWESST's common stock is listed on the TSX-Venture Exchange ("TSX-V") under the stock symbol of KWE, on the Nasdaq Capital Market ("Nasdaq") under the stock symbol of KWE and on the Frankfurt Stock Exchange under the stock symbol of 62U. Additionally, warrants issued in the United States are also listed on the Nasdaq under the stock symbol of KWESW. Effective May 1, 2023, the warrants issued in Canada are listed on the TSX-V under the stock symbol of KWE.WT.U.

## b) Reverse Stock Split

In August 2022, we submitted a Form F-1 Registration Statement to the U.S. Securities and Exchange Commission and applied to have its common shares listed on Nasdaq. In connection with KWESST's listing application on Nasdaq, we effected a one for seventy (1-for-70) reverse stock split of its common stock on October 28, 2022 (the "Reverse Split"). Accordingly, all shareholders of record at the opening of business on October 28, 2022, received one issued and outstanding common share of KWESST in exchange for seventy outstanding common shares of KWESST. No fractional shares were issued in connection with the Reverse Split. All fractional shares created by the Reverse Split were rounded to the nearest whole number of common shares, with any fractional interest representing 0.5 or more common shares entitling holders thereof to receive one whole common share.

Effective on the date of the Reverse Split, the exercise price and number of common shares issuable upon the exercise of outstanding stock options were proportionately adjusted to reflect the Reverse Split. The restricted share units ("RSUs") and performance stock units ("PSUs") have also been adjusted for the Reverse Split. While the number of warrants has not changed as a result of the Reverse Split; the conversion rate for each warrant was adjusted from one common share to 0.01428571 common share. All information respecting outstanding common shares and other securities of KWESST, including net loss per share, in the current and comparative periods presented herein give effect to the Reverse Split.

## 2. Basis of preparation

## (a) Going concern

These unaudited condensed consolidated interim financial statements have been prepared assuming we will continue as a going concern.

As an early-stage company, we have not yet reached commercial production for most of our products and have incurred significant losses and negative operating cash flows from inception that have primarily been funded from financing activities. We have incurred a \$3.4 million net loss and negative operating cash flows of \$9.2 million for the six months ended March 31, 2023 (2022 - \$5.5 million net loss and negative operating cash flows of \$2.9 million). At March 31, 2023, we had \$2.2 million in working capital (September 30, 2022 – negative \$5.4 million).

Notes to Unaudited Condensed Consolidated Interim Financial Statements Three and six months ended March 31, 2023, and 2022 (Expressed in Canadian dollars, except share amounts)

Our ability to continue as a going concern and realize our assets and discharge our liabilities in the normal course of business is dependent upon closing timely additional sales orders, timely commercial launch of new products, and the ability to raise additional debt or equity financing, when required. There are various risks and uncertainties affecting our future financial position and our performance including, but not limited to:

- The market acceptance and rate of commercialization of our product offerings;
- Ability to successfully execute our business plan;
- Ability to raise additional capital at acceptable terms;
- General local and global economic conditions, including the ongoing COVID-19 pandemic and the global disruption from Russia's invasion of Ukraine.

Our strategy to mitigate these material risks and uncertainties is to execute timely a business plan aimed at continued focus on revenue growth, product development and innovation, improving overall gross profit, managing operating expenses and working capital requirements, and securing additional capital, as needed.

Failure to implement our business plan could have a material adverse effect on our financial condition and/or financial performance. There is no assurance that we will be able to raise additional capital as they are required in the future. Accordingly, there are material risks and uncertainties that may cast significant doubt about our ability to continue as a going concern.

These condensed consolidated interim financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities and reported expenses that may otherwise be required if the going concern basis was not appropriate.

#### (b) Statement of compliance

These unaudited condensed consolidated interim financial statements have been prepared in accordance with IAS 34, Interim Financial Reporting, ("IAS 34") as issued by the International Accounting Standards Board ("IASB"). They do not include all the information required for a complete set of financial statements prepared in accordance with International Financial Reporting Standards ("IFRS") and should be read in conjunction with our annual consolidated financial statements for the year ended September 30, 2022. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in our financial position and performance since the last annual consolidated financial statements as at and for the year ended September 30, 2022.

These unaudited condensed consolidated interim financial statements were authorized for issue by the Board of Directors on May 11, 2023.

#### (c) Basis of consolidation

These unaudited condensed consolidated interim financial statements incorporate the financial statements of KWESST and the entities it controls.

Control is achieved where we have the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities, are exposed to, or have rights to, variable returns from our involvement with the entity and have the ability to affect those returns through its power over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to us until the date on which control ceases. Profit or loss of subsidiaries acquired during the year are recognized from the date of acquisition or effective date of disposal as applicable. All intercompany transactions and balances have been eliminated.

Notes to Unaudited Condensed Consolidated Interim Financial Statements Three and six months ended March 31, 2023, and 2022 (Expressed in Canadian dollars, except share amounts)

At March 31, 2023, we have the following wholly-owned subsidiaries:

	Location	Equity %
KWESST Inc.	Ottawa, Canada	100%
2720178 Ontario Inc.	Bowmanville, Canada	100%
Police Ordnance Company Inc.	Bowmanville, Canada	100%
KWESST U.S. Holdings Inc.	Delaware, Canada	100%
KWESST Defense Systems U.S. Inc.	Virginia, United States	100%
KWESST Public Safety Systems U.S. Inc.	Virginia, United States	100%
KWESST Public Safety Systems Canada Inc.	Ottawa, Canada	100%

#### (d) Functional and presentation currency

These financial statements are presented in Canadian dollars ("CAD"), our functional currency and presentation currency.

#### (e) Basis of measurement

The consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments measured at fair value. Historical cost is generally based on the fair value of the consideration given in exchange for assets.

#### (f) Use of estimates and judgments

The preparation of the unaudited condensed consolidated interim financial statements in accordance with IFRS requires management to make judgments, estimates, and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income, expenses, and disclosure of contingent liabilities. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognized prospectively.

#### Judgments

Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognized in these consolidated financial statements are the same as disclosed in Note 2(f) of the consolidated financial statements for the year ended September 30, 2022, except for the following new item:

• Note 12 – warrant liabilities: whether the determination of our stock volatility and the expected life of the warrant liabilities are reasonable considering our limited operating history, both are significant inputs in the valuation model to fair value the warrant liabilities issued in the U.S IPO and Canadian Offering.

#### **Estimates**

Information about assumptions and estimation uncertainties at March 31, 2023 that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities in the next financial year are the same as disclosed in Note 2(f) of the consolidated financial statements for the year ended September 30, 2022.

Notes to Unaudited Condensed Consolidated Interim Financial Statements Three and six months ended March 31, 2023, and 2022 (Expressed in Canadian dollars, except share amounts)

## **COVID-19 Uncertainties**

There is no change to our COVID-19 assessment from the disclosure provided in Note 2(f) of the consolidated financial statements for the year ended September 30, 2022.

#### 3. Significant accounting policies

During the six months ended March 31, 2023, the accounting policies in these condensed consolidated interim financial statements are the same as those applied in KWESST's consolidated financial statements as at and for the year ended September 30, 2022.

#### 4. Acquisition

On December 15, 2021, we acquired 2720178 Ontario Inc., an Ontario (Canada) corporation, which owns all of the issued and outstanding shares of Police Ordnance Company Inc., an Ontario (Canada) corporation (together, "Police Ordnance"), herein referred as the "Police Ordnance Acquisition". Located in Bowmanville, Ontario, with ancillary operations in Florida, Police Ordnance owns all intellectual properties to the ARWEN<sup>TM</sup> product line of launchers, and a proprietary line of 37 mm cartridges designed for riot control and tactical teams. Police Ordnance has law enforcement customers across Canada, the United States, and abroad. The Police Ordnance Acquisition provides us with a strategic opportunity to leverage its law enforcement customer base to accelerate growth within its specialty ordnance business.

We accounted for the acquisition of Police Ordinance pursuant to IFRS 3, Business Combinations.

Consideration Transferred:

The purchase consideration comprised of the following:

	Number	Fair Value
Common shares	3,965	\$ 377,503
Warrants	200,000	\$ 132,000
Contingent shares	875	\$ 83,319
Total fair value purchase consideration		\$ 592,822

The warrants are exercisable at \$1.72 each and will expire on December 15, 2024. As a result of the Reverse Split (see Note 1(b)), each warrant converts into 0.01428571 common share or 70 warrants to receive one common share of KWESST.

We issued the 875 contingent common shares to the sellers in April 2022 following the fulfillment of the financial milestone as defined in the share purchase agreement.

We have estimated the fair value as follows:

- Common shares: based on KWESST's closing stock price on December 15, 2021.
- Warrants: based on using the Black Scholes option model with the following key inputs: a) exercise price of \$1.72, 1/70 of the underlying stock price of \$1.36, risk free rate of 1.04%, expected life of three years, and expected volatility of 84.7%.
- Contingent shares: based on KWESST's closing stock price on December 15, 2021, and high probability of achieving the financial milestone as defined in the share purchase agreement.

Notes to Unaudited Condensed Consolidated Interim Financial Statements Three and six months ended March 31, 2023, and 2022 (Expressed in Canadian dollars, except share amounts)

The net cash inflow as at the closing of the acquisition was as follows:

Net cash inflow on acquisition	\$ 162,547
less: consideration paid in cash	-
Cash assumed on acquisition	\$ 162,547

#### *Net Assets Acquired:*

The purchase consideration was allocated to Police Ordnance's net assets as follows:

Total purchase consideration at fair value	\$ 592,822
Police Ordnance's net assets:	
Cash	162,547
Trade and other receivables	104,432
Inventories	352,685
Intangible assets:	
Purchase orders	100,000
Customer relationships	50,000
ARWEN <sup>™</sup> tradename	44,000
Accounts payable and accrued liabilities	82,963
Corporate tax liability	32,338
Contract liabilities	29,861
Borrowings	26,238
Deferred tax liabilities	49,442
Net assets at fair value	\$ 592,822

As a result of the above purchase price allocation, we have recorded no goodwill for the Police Ordnance Acquisition.

#### Impact on KWESST's Results of Operations:

The results of operations of Police Ordnance are included in these unaudited condensed consolidated interim statements of net loss and comprehensive loss from December 16, 2021. If the acquisition had occurred on October 1, 2021, management estimates that Police Ordnance would have contributed approximately \$128,600 and \$282,300 of revenue and approximately \$47,300 and \$59,100 of net loss to KWESST's operating results for the three and six months ended March 31, 2022, respectively. In determining these amounts, management has assumed that the fair value adjustments that arose on the date of the acquisition would have been the same if the acquisition had occurred on October 1, 2021.

We incurred immaterial acquisition-related costs.

Notes to Unaudited Condensed Consolidated Interim Financial Statements Three and six months ended March 31, 2023, and 2022 (Expressed in Canadian dollars, except share amounts)

## 5. Trade and other receivables

The following table presents trade and other receivables for KWESST:

	March 31, September		ptember 30,	
		2023		2022
Trade receivables	\$	74,458	\$	114,877
Unbilled revenue		5,673		8,881
Sales tax recoverable		128,895		48,124
Other receivable		3,494		-
Total	\$	212,520	\$	171,882

There was no impairment of trade and other receivables during the six months ended March 31, 2023 (2022 – \$nil).

The following table presents changes in unbilled receivables:

	March 31, 2023	Se	eptember 30, 2022
Balance, beginning of period	\$ 8,881	\$	308,728
Revenue billed during the period Revenue in excess of billings, net of amounts transferred	(3,670)		(308,728)
to trade receivables	462		8,881
Balance, end of period	\$ 5,673	\$	8,881
Current	\$ 5,673	\$	8,881
Non-current	\$ -	\$	-

## 6. Inventories

The following table presents a breakdown of inventories:

	March 31,	Se	ptember 30,
	2023		2022
Finished goods	\$ 44,673	\$	49,643
Work-in-progress	353,240		21,350
Raw materials	474,607		322,545
Total	\$ 872,520	\$	393,538

There was no impairment of inventories during the six months ended March 31, 2023 (2022 - \$nil).

Notes to Unaudited Condensed Consolidated Interim Financial Statements Three and six months ended March 31, 2023, and 2022 (Expressed in Canadian dollars, except share amounts)

## 7. Intangible assets

The following table shows the movement in intangible assets since September 30, 2022:

								Customer			
	Phantom <sup>TM</sup>	$PARA\ OPS^{^{TM}}$	PA	RA OPS <sup>TM</sup>	4	ARWEN™	Re	lationship	]	Purchase	
Cost	System	System		Patent	T	radename		S		Orders	Total
Balance at September 30, 2022	\$ 1,149,585	\$ 3,469,215	\$	28,783	\$	37,032	\$	46,041	\$	12,198	\$4,742,854
Additions	19,855	570,414		8,256		-		-		-	598,525
Amortization	-	(134,654)		-		(4,400)		(2,500)		-	(141,554)
Recognition of open orders	-	-		-		-		-		(7,811)	(7,811)
Balance at March 31, 2023	\$ 1,169,440	\$ 3,904,975	\$	37,039	\$	32,632	\$	43,541	\$	4,387	\$5,192,014

At March 31, 2023, management concluded there was no impairment on the intangible assets (2022 - \$nil). The development of PARA OPS<sup>TM</sup> was substantially completed during the six months ended March 31, 2023 and amortization of \$134,654 was recognized in General and administrative expenses. Management determined the estimated useful life to be five years.

#### 8. Accounts payable and accrued liabilities

The following table presents a breakdown of our accounts payable and accrued liabilities:

	March 31,		S	September 30,
		2023		2022
Trade payable	\$	450,334	\$	2,292,954
Accrued liabilities		842,070		1,045,409
Salary and vacation payable		207,249		1,121,118
Total	\$	1,499,653	\$	4,459,481

## 9. Related party transactions

At March 31, 2023, there was \$177,500 (September 30, 2022 - \$672,531) outstanding in accounts payable and accrued liabilities due to our officers and directors for unpaid wages, director fees, and expense reimbursements.

## 10. Borrowings

The following is a reconciliation of borrowings since September 30, 2022:

	Cl	EBA Term	I	March 2022	Αι	igust 2022		Total
		Loans		Loans		Loans	В	orrowings
Balance, September 30, 2022	\$	78,796	\$	1,764,630	\$	435,348	\$	2,278,774
Accrued interest and accretion expense		11,204		274,887		179,096		465,187
Interest paid		-		(39,517)		(63,661)		(103,178)
Repayment of principal		(70,000)		(1,988,000)		(275,315)	(	2,333,315)
Settled in equity (Notes 12 and 18)		-		(12,000)		(275,468)		(287,468)
Forgivable amount		(20,000)		-		-		(20,000)
Balance, March 31, 2023	\$	-	\$	-	\$	-	\$	-

There were no changes to KWESST's RBC Credit Facility since September 30, 2022.

Notes to Unaudited Condensed Consolidated Interim Financial Statements Three and six months ended March 31, 2023, and 2022 (Expressed in Canadian dollars, except share amounts)

## 11. Contract liabilities

The following is a reconciliation of contract liabilities since September 30, 2022:

	March 31,
	2023
Balance, beginning of period	\$ 47,271
Amounts invoiced and revenue deferred	267,529
Recognition of deferred revenue included in the	
balance at the beginning of period	(47,528)
Balance, end of period	\$ 267,272

#### 12. Warrant liabilities

The following is a reconciliation of warrant liabilities since September 30, 2022:

	1	U.S. IPO and Canadian Offering						Settlemen	nt
	allo 2022 Warrants		Over- otment Pre- Funded Warrants		Over- allotment Warrants		Warrants	Total	
Balance, beginning of period	\$	-	\$	-	\$	-	\$	-	\$ -
Initial recognition	4,61	7,451		832,698		536,681		80,617	6,067,447
Gain on revaluation of financial instruments	(2,88	9,992)		(164,326)		(335,070)		(51,884)	(3,441,272)
Exchange gain on revaluation	(2	4,610)		(5,878)		(3,691)		-	(34,179)
Balance, end of period	\$1,70	2,849	\$	662,494	\$	197,920	\$	28,733	\$ 2,591,996
Number of outsanding securities as at March 31, 2023	3,22	6,392		199,000		375,000		56,141	3,856,533

## U.S. IPO and Canadian Offering

On December 9, 2022, we closed an underwritten U.S. public offering (the "U.S. IPO") and an underwritten Canadian offering (the "Canadian Offering") for aggregate gross proceeds of CAD\$19.4 million (US\$14.1 million) (see Note 13(a)). As part of the U.S. IPO and Canadian Offering, we have issued 3,226,392 warrants (the "2022 Warrants") with an exercise price of US\$5.00 per share. Additionally, the U.S. underwriter exercised its over-allotment option to purchase:

- 199,000 Pre-Funded Warrants with an exercise price of US\$0.01 per share for \$3.81024 per pre-funded warrant (net of underwriter discount);
- 375,000 warrants with exercise price of US\$5.00 per share for \$0.0001 per warrant;

Refer to Note 13(a) for further information on the U.S. IPO and Canadian Offering.

Under IFRS, the above securities are classified as financial liabilities (referred herein as "warrant liabilities") because the exercise price is denominated in U.S. dollars, which is different to our functional currency (Canadian dollars). Accordingly, the ultimate proceeds in Canadian dollars from the potential exercise of the above securities are not known at inception. These financial liabilities are classified and measured at FVTPL (see Note 3(c) of the audited consolidated financial statements for the year ended September 30, 2022). Gains on revaluation of the warrant liabilities are presented in Other income (expenses) on the condensed consolidated interim statements of net loss and comprehensive loss.

#### Warrant liabilities

While the warrants issued in the U.S. IPO were listed on Nasdaq and closed at US\$0.90 per warrant on December 9, 2022, management concluded that this closing price was not reflective of an active market due to short trading

Notes to Unaudited Condensed Consolidated Interim Financial Statements Three and six months ended March 31, 2023, and 2022 (Expressed in Canadian dollars, except share amounts)

window and therefore not representative of fair value. Accordingly, at inception, the 2022 Warrants were measured at fair value using the Black Scholes option pricing model (Level 2). We used the following assumptions:

		0	ver-allotment	
	2022		Pre-Funded	Over-allotment
	Warrants		Warrants (1)	Warrants (2)
Number of dilutive securities	3,282,533		199,000	375,000
Exercise price (in USD)	\$ 5.00	\$	0.01	
Share price (in USD)	\$ 4.13	\$	3.08	
Expected life	2.50			
Dividend	\$ -			
Volatility	75%			
Risk free rate	4.20%			
Exchange rate (USD/CAD)	\$ 1.363			
Fair value per warrant (CAD)	\$ 1.43	\$	4.18	\$ 1.43

<sup>(1)</sup> Fair value is measured at the underlying common share closing price on Nasdaq on December 9, 2022, less US\$0.01 exercise price.

The share price (in USD) for the over-allotment pre-funded warrants was based on the estimated fair value of the common shares issued on December 9, 2022, by deducting the fair value of the warrants of US\$1.05 from the US\$4.13 Unit price and the exercise price of US\$0.01 (see Note 13(a)).

Based on the above fair value, the issuance of the over-allotment pre-funded warrants and warrants to the underwriter resulted in a non-cash charge of \$251,877, which is included in the change in fair value of warrant liabilities in the condensed consolidated interim statements of net loss and comprehensive loss.

At March 31, 2023, we remeasured the fair value of these warrants using the following assumptions:

	v	2022 Varrants <sup>(1)</sup>	ver-allotment Pre-Funded Warrants <sup>(2)</sup>	Over-allotment Warrants (1)
Number of securities		3,282,533	199,000	375,000
Nasdaq closing price (in USD)	\$	0.39	\$ 2.47	\$ 0.39
Exchange rate (USD/CAD)	\$	1.353	\$ 1.353	\$ 1.353
Fair value per warrant (CAD)	\$	0.53	\$ 3.33	\$ 0.53

<sup>(1)</sup> Fair value is based on the Nasdaq closing pricing on March 31, 2023 for the warrants.

Including the non-cash charge for the issuance of the over-allotment pre-funded warrants and warrants to the underwriter, we recognized \$1,838,972 and \$3,189,395 as a change in fair value of warrant liabilities during the three and six months ended March 31, 2023, respectively, which was reported in the condensed consolidated net loss and comprehensive loss.

## December 2022 Debt Settlement

On December 13, 2022, we have entered into share for debt arrangements with existing lenders (see Note 13(a)), which resulted in issuing 56,141 Units, same terms as the Units as issued in the Canadian Offering except that

<sup>(2)</sup> Same fair value as calculated for Warrants.

<sup>(2)</sup> Fair value is measured at the Nasdaq closing price on March 31, 2023, for the underlying common stock less US\$0.01 exercise price.

Notes to Unaudited Condensed Consolidated Interim Financial Statements Three and six months ended March 31, 2023, and 2022 (Expressed in Canadian dollars, except share amounts)

the underlying securities are subject to a four-month hold period. Accordingly, this resulted in issuing 56,141 common shares and 56,141 warrant liabilities with an exercise price of US\$5.00 per share and maturing on December 13, 2027. We initially recorded the fair value of the warrant liabilities using the Black Scholes option pricing model with an underlying stock price equivalent to the unit price of US\$4.13.

At March 31, 2023, we remeasured the fair value of these warrant liabilities using the Nasdaq closing price on March 31, 2023 of US\$0.39. The remeasurement resulted in a change in fair value of warrant liabilities of \$27,535 and \$51,884 for the three and six months ended March 31, 2023, respectively, which was reported in the condensed consolidated net loss and comprehensive loss.

## 13. Share capital and Contributed Surplus

## a) Share capital

Authorized

KWESST is authorized to issue an unlimited number of common shares.

**Issued Common Shares** 

The following is a summary of changes in outstanding common shares since September 30, 2022:

	Number	Amount
Balance at September 30, 2022	773,225	\$ 19,496,640
Issued for U.S. IPO and Canadian Offering	3,226,392	\$ 13,675,120
Issued for debt settlements	56,134	\$ 233,485
Issued for conversion of stock units	13,784	\$ 528,207
Issued for warrant exercise	3,571	\$ 60,000
Less: share offering costs for the period		\$ (3,050,278)
Balance at March 31, 2023	4,073,106	\$ 30,943,174

## U.S. IPO and Canadian Offering

On December 9, 2022, we closed the U.S. IPO and the Canadian Offering. In the U.S. IPO, we sold 2.5 million units at a public offering price of USD \$4.13 per unit (the "Unit"), consisting of one share of common stock and one warrant to purchase one share of common stock ("Warrant"). The Warrants have a per share exercise price of USD \$5.00, and can be exercised immediately. In connection with the closing of the U.S. IPO, the underwriter partially exercised its over-allotment option to purchase an additional 199,000 pre-funded common share purchase warrants ("Pre-Funded Warrants") at US\$4.12 (before underwriter discount) and 375,000 option warrants to purchase common shares at US\$0.0001 each. A Pre-Funded Warrant is a financial instrument that requires the holder to pay little consideration (exercise price of US\$0.01) to receive the common share upon exercise of the Pre-Funded Warrant (see Note 14). The holder of Pre-Funded Warrants has no voting rights. All of these warrants expire on December 9, 2027.

In the Canadian Offering, we sold 726,392 units, each consisting of one common share and one warrant to purchase one common share, at a price to the public of USD \$4.13 per unit. The warrants will have a per common share exercise price of USD \$5.00, are exercisable immediately and expire in five years on December 9, 2027. Effective May 1, 2023, the warrants are listed on the TSX-V under the stock symbol of KWE.WT.U.

The closing of the U.S. IPO and Canadian Offering resulted in aggregate gross proceeds of CAD\$19.4 million (USD \$14.1 million), before deducting underwriting discounts and offering expenses.

Notes to Unaudited Condensed Consolidated Interim Financial Statements Three and six months ended March 31, 2023, and 2022 (Expressed in Canadian dollars, except share amounts)

The common shares of KWESST and the Warrants sold in the U.S. IPO began trading on the Nasdaq Capital Market under the symbols "KWE" and "KWESW", respectively, on December 7, 2022.

ThinkEquity acted as sole book-running manager for the U.S. IPO and PI Financial acted as sole book-running manager for the Canadian Offering.

### **Accounting Treatment**

Refer to Note 12 for the accounting of the warrants issued in the U.S. IPO and Canadian Offering.

#### Brokers' Compensation and Share Offering Costs

As consideration for the services provided in connection with the U.S. IPO, ThinkEquity received: (a) a broker-dealer cash commission of US\$835,000 (or CAD\$1,138,105) equal to 7.5% of the gross offering proceeds of the U.S. Offering and (b) underwriter warrants (the "U.S. Underwriter Warrants") to purchase up to 134,950 common shares equal to 5% of the common shares and pre-funded common share purchase warrants issued under the U.S. Offering. Each U.S. Underwriter Warrant is exercisable to acquire one common share at a price of US\$5.1625, exercisable as of June 4, 2023, and expiring on December 9, 2027.

As consideration for the services provided in connection with the Canadian Offering, PI Financial received: (a) a cash commission of approximately US\$210,000 (or CAD\$286,230); and (b) 50,848 compensation options (the "Canadian Compensation Options"). Each Canadian Compensation Option is exercisable to acquire one Canadian Unit at a price of US\$4.13 and expiring on December 9, 2024.

In addition to the above brokers' compensation, we also incurred US\$2.1 million share offering costs (or CAD\$2.8 million) for the U.S. IPO and Canadian Offering, of which CAD\$628,262 was incurred and deferred at September 30, 2022.

The total brokers compensation (including fair value of U.S. Underwriter Warrants and Canadian Compensation Options) and share offering costs was US\$3.2 million (or CAD\$4.4 million). This total was allocated proportionately to the fair value of common shares and warrant liabilities. Accordingly, CAD\$1.3 million allocated to warrant liabilities were expensed during the six months ended March 31, 2023.

#### Shares for Debt Settlement

We have entered into share for debt arrangements with existing lenders, which closed on December 13, 2022, following TSXV's conditional approval. This resulted in issuing 56,141 Units to settle \$12,000 of the March 2022 Loans and USD\$223,321 (or CAD\$302,197) of the August 2022 Loans, including unpaid accrued interest and 10% premium at maturity (the "Debt Settlements") – see Note 10. The terms of the Units are the same as the Units issued in the Canadian Offering.

Notes to Unaudited Condensed Consolidated Interim Financial Statements Three and six months ended March 31, 2023, and 2022 (Expressed in Canadian dollars, except share amounts)

## b) Warrants

The following is a summary of changes in outstanding warrants since September 30, 2022:

	Number of	Weighted
	warrants	average exercise price
Outstanding at September 30, 2022	13,417,156	\$ 0.78
Issued (Note 13(a))	3,991,483	\$ 6.44
Exercised	(250,000)	\$ 0.50
Outstanding at March 31, 2023	17,158,639	\$ 2.10
Exercisable at March 31, 2023	16,648,689	\$ 2.09

## U.S. Underwriter Warrants

In the U.S. IPO, we issued 134,950 warrants ("U.S. Underwriter Warrants"). Each U.S. Underwriter Warrant is exercisable to acquire one common share at US\$5.1625 for a period of 5 years (expiring on December 9, 2027). Management estimated the fair value of these warrants using the Black Scholes option model with the following inputs:

Fair value per warrant (CAD)	\$	1.40
Exchange rate (USD/CAD)	\$	1.363
Risk free rate		4.20%
Volatility		75%
Dividend	\$	-
Expected life		2.50
Share price (in USD)	\$	3.08
Exercise price (in USD)	\$	5.16
Number of dilutive securities	13	34,950

We have recorded \$189,592 as the fair value for the U.S. Underwriter Warrants, with an equal offset to share offering costs (a non-cash transaction).

Notes to Unaudited Condensed Consolidated Interim Financial Statements Three and six months ended March 31, 2023, and 2022 (Expressed in Canadian dollars, except share amounts)

The following table provides additional information on the total outstanding warrants at March 31, 2023:

	Number	Conversion ratio			
		to Common Shares		Book value	Expiry Date
Classified as Equity	outstanding	to common sum to		Door mue	Ziipii j Ziive
Founders' warrants:					
Exercise price of \$0.20	5,520,000	70 for 1	\$	1,013	January 1, 2024
Exercise price of \$0.20	1,900,000	70 for 1	\$	18,865	June 14, 2024
April 2021 equity financing:					
Exercise price of \$1.75	3,274,657	70 for 1	\$	785,918	April 29, 2023
Exercise price of \$1.75	40,000	70 for 1	\$	9,600	August 25, 2023
LEC's warrants:					
Exercise price of \$0.70	500,000	70 for 1	\$	425,000	April 29, 2026
September 2021 equity financing:					
Exercise price of \$2.35	750,000	70 for 1	\$	390,000	September 16, 2023
Broker warrants:	,			,	1
Exercise price of \$1.75	137,499	70 for 1	2	33,000	April 29, 2023
Exercise price of \$2.00	45,000	70 for 1		32,400	September 16, 2023
-	12,000	70 101 1	Ψ	32,100	September 10, 2023
Acquisition of Police Ordnance (Note 4): Exercise price of \$1.72	200,000	70 for 1	¢	132,000	December 15, 2024
•	200,000	70 101 1	Φ	132,000	December 13, 2024
July 2022 equity financing:	000.000	<b>50.0</b> 1	Φ.	<b>72</b> 000	
Exercise price of \$0.285	800,000	70 for 1	\$	72,000	July 14, 2024
December 2022 U.S. Underwriter Warrants					
Exercise price of US\$5.1625	134,950	1 for 1	\$	189,592	December 6, 2024
	13,302,106		\$	2,089,388	
Classified as liability					
December 2022 public offerings:					
Exercise price of US\$5.00	3,226,392	1 for 1	\$	1,702,849	December 9, 2027
December 2022 Pre-Funded Warrants					
Exercise price of US\$0.01	199,000	1 for 1	\$	662,494	No expiry
-	,		•		
December 2022 Option Warrants Exercise price of US\$5.1625	375,000	1 for 1	¢	197,920	December 9, 2024
•	373,000	1 101 1	Φ	177,720	December 9, 2024
December 2022 debt settlement	56.141	1.6.1	Ф	20.722	D 1 0 2027
Exercise price of US\$5.00	56,141	1 for 1	\$	28,733	December 9, 2027
	3,856,533			2,591,996	
Total outstanding warrants	17,158,639		\$	4,681,384	

# c) Contributed Surplus

**Broker Compensation Options** 

In the Canadian Offering, we issued 50,848 Canadian Compensation Options. Each Canadian Compensation Option is exercisable to acquire one Unit, as defined in Note 13(a), at a price equal to US\$4.13 for a period of two years (expiring on December 9, 2024). Based on the structure of the Compensation Option, management estimated its fair value using the Monte Carlo method (Level 2). We used the following key inputs in the Monte Carlo model (100,000 simulations):

Notes to Unaudited Condensed Consolidated Interim Financial Statements Three and six months ended March 31, 2023, and 2022 (Expressed in Canadian dollars, except share amounts)

		Initial
	Re	cognition
Number of securities		50,848
Exercise price - compensation option (in USD)	\$	4.13
1-Year CAD/USD Forward Exchange Rate	\$	1.3560
Exercise price - compensation warrant (in USD)	\$	5.00
2-Year CAD/USD Forward Exchange Rate	\$	1.3483
Share price (in CAD)	\$	4.20
Expected life - compensation option		1.00
Expected life - compensation warrant		2.50
Dividend	\$	-
Volatility - compensation option		90%
Volatility - compensation warrant		75%
Risk free rate - compensation option		4.38%
Risk free rate - compensation warrant		3.15%
Fair value per compensation option (CAD)	\$	2.46

We have recorded \$125,086 of Canadian Compensation Options in contributed surplus, with an equal offset to share offering costs (a non-cash transaction).

#### Share-based compensation

On March 31, 2023, KWESST shareholders approved the renewal of the Long-Term Incentive Plan (the "LTIP"). Additionally, the disinterested shareholders of KWESST approved an amendment to the LTIP to increase the number of RSUs, PSUs, DSUs, and SARs (collectively "Share Units") authorized for issuance pursuant to the LTIP from 60,682 to 407,274 Share Units. Accordingly, we have 497,274 Share Units available for future grants.

Further, the disinterested shareholders of KWESST approved to revise the exercise price of 50,981 stock options to \$3.60, the closing price of KWESST common shares on the TSX-V on March 31, 2023. In accordance with IFRS 2, this resulted in an immediate fair value increase of \$77,001 included in share-based compensation, with an offset to contributed surplus for the three and six months ended March 31, 2022.

We did not grant any stock options, RSUs, PSUs, and SARs, pursuant to our LTIP during the six months ended March 31, 2023. Accordingly, we had 51,338 outstanding stock options at March 31, 2023. The remaining available stock option pool for future grants was 351,989 at March 31, 2023.

For the three and six months ended March 31, 2023, we recorded share-based compensation of \$151,981 and \$277,047, respectively (2022 - \$422,931 and \$1,350,461).

## 14. Earnings (loss) per share

The following table summarizes the calculation of the weighted average basic number of basic and diluted common shares to calculate the earnings (loss) per share as reported in the condensed consolidated interim statements of net loss and comprehensive loss:

Notes to Unaudited Condensed Consolidated Interim Financial Statements Three and six months ended March 31, 2023, and 2022 (Expressed in Canadian dollars, except share amounts)

	Three months	Three months	Six months	Six months
	ended	ended	ended	ended
	March 31,	March 31,	March 31	March 31,
	2023	2022	2023	2022
Issued common shares, beginning of period	4,265,984	707,271	773,225	699,509
Effect of shares issued from:				
December 2022 U.S. IPO and Canadian Offering (Note 13)	-	-	1,985,472	-
Over-allotment Pre-Funded Warrants (Note 12)	-	-	122,462	-
Debt settlements (Note 13)	-	-	33,314	123
Conversion of stock units	5,610	1,007	9,490	545
Exercise of warrants	-	1,361	1,766	2,439
Acquisition of Police Ordnance (Note 4)	-	-	-	2,309
Issuance of bonus shares (Note 10)	-	2,762	-	1,366
Weighted average number of basic common shares	4,271,594	712,401	2,925,729	706,291
Dilutive securities:	-	-	-	-
Weighted average number of dilutive common shares	4,271,594	712,401	2,925,729	706,291

At March 31, 2023 and 2022, all dilutive securities were anti-dilutive because we incurred a net loss for the above periods.

As the \$0.01 exercise price per Pre-Funded Warrant is non-substantive, the 199,000 Pre-Funded Warrants issued in the U.S. IPO are included in the basic net loss per share calculation.

## 15. Revenue

The following table, revenue from contracts with customers is disaggregated by primary geographical market, major products and service lines, and timing of revenue recognition.

	Three months ended		Three months ended		Six months ended		ended	
	IV	<b>March 31, 2023</b>	M	arch 31, 2022	IV	Iarch 31, 2023	M	arch 31, 2022
Major products / service lines								
Digitization	\$	68,788	\$	139,975	\$	264,004	\$	156,615
Non-lethal		92,615		26,166		213,492		26,166
Other		- -		110		1,240		935
	\$	161,403	\$	166,251	\$	478,736	\$	183,716
Primary geographical markets								
United States	\$	21,398	\$	4,411	\$	27,319	\$	21,051
Canada		140,005		161,840		451,417		162,665
	\$	161,403	\$	166,251	\$	478,736	\$	183,716
Timing of revenue recognition								
Products and services transferred over time	\$	68,788	\$	155,649	\$	264,004	\$	172,289
Products transferred at a point in time		92,615		10,602		214,732		11,427
	\$	161,403	\$	166,251	\$	478,736	\$	183,716

At March 31, 2023, KWESST's contracted not yet recognized revenue was \$1,029,889 (2022 – 157,901), of which 78.59% of this amount is expected to be recognized over the next 12 months with the remaining 21.41% expected to be recognized in 2 to 3 years.

Notes to Unaudited Condensed Consolidated Interim Financial Statements Three and six months ended March 31, 2023, and 2022 (Expressed in Canadian dollars, except share amounts)

For the three months ended March 31, 2023, two customers accounted for 31.84% and 13.45% (2022 – one customer accounted for 84.19%) of revenue. For the six months ended March 31, 2023, three customers accounted for 36.25%, 15.51%, and 10.56% (2022 – one customer accounted for 85.25%) of total revenue.

#### 16. Net finance costs

The following table presents a breakdown of net finance costs for the following periods:

	March 31,	Three months ended March 31, 2022	March 31,	Six months ended March 31, 2022
Finance costs from:	2023	2022	2023	2022
Unsecured loans	\$ -	\$ 28,089	\$ 453,983	\$ 28,089
Accretion cost - accrued royalties liability	42,626	35,322	86,315	73,506
Lease obligations	6,332	8,396	13,085	16,028
Other	-	1,334	63,204	4,959
Total financing costs	48,958	73,141	616,587	122,582
Interest income	(37,851)	(662)	(51,473)	(2,461)
Gain on debt settlement (Note 10)	-	-	(430)	-
Gain on government grant (Note 10)	-	-	(10,000)	-
Net finance costs	\$ 11,107	\$ 72,479	\$ 554,684	\$ 120,121

#### 17. Financial instruments

For the three and six months ended March 31, 2023, there were no material changes to our financial risks as disclosed in Note 22 of the audited consolidated financial statements for the year ended September 30, 2022, except for the following:

## Foreign currency risk

For the three and six months ended March 31, 2023, certain of our revenues were denominated in U.S. dollar and we also procure certain raw materials denominated in U.S. dollar for product development. Further, we raised gross proceeds of US\$14.1 million in the U.S. IPO and Canadian Offering (see Note 13), including the issuance of warrants with exercise price denominated in U.S. dollar (see Note 12). Accordingly, we are exposed to the U.S. dollar currency. Where a natural hedge cannot be achieved, a significant change in the U.S. dollar currency could have a significant effect on our financial performance, financial position and cash flows. Currently, we do not use derivative instruments to hedge its U.S. dollar exposure.

At March 31, 2023, we had the following net U.S. dollar exposure:

		-
		<b>Total USD</b>
Net liabilities in U.S. subsidiary	\$	(1,475)
US denominated from other:		
Assets	\$	1,899,065
Liabilities	(	1,748,249)
		150,816
Total net US dollar exposure	\$	149,341
Impact to profit or loss if 5% movement in the US dollar	\$	7,467

During the three and six months ended March 31, 2023, we recorded foreign exchange loss of \$19,684 and \$150,040, respectively (2022 - \$9,044 and \$299).

Notes to Unaudited Condensed Consolidated Interim Financial Statements Three and six months ended March 31, 2023, and 2022 (Expressed in Canadian dollars, except share amounts)

Liquidity risk

At March 31, 2023, our contractual obligations were as follows:

Payment due:	Total		Within 1 Year		1 to 3 years		3 to 5 years	
Minimum royalty commitments	\$	2,350,000	\$	_	\$	350,000	\$	2,000,000
Accounts payable and accrued liabilities		1,499,653		1,499,653		-		-
Lease obligations		424,418		127,287		255,423		41,708
Short-term rental obligations		67,933		67,933		-		-
Total contractual obligations	\$	4,342,004	\$	1,694,873	\$	605,423	\$	2,041,708

At March 31, 2023, we had \$4.0 million in cash and \$2.2 million in working capital (see Note 2(a)).

#### 18. Supplemental cash flow information

The following table presents changes in non-cash working capital:

	Six months ended March 31, 2023	Six months ended March 31, 2022
Trade and other receivables	\$ (40,638)	\$ 667,151
Inventories	(478,982)	(11,059)
Prepaid expenses	(1,385,502)	247,534
Intangible assets	7,811	-
Accounts payable and accrued liabilities	(1,857,040)	19,056
Contract liabilities	220,001	157,901
Corporate taxes payable	-	(28,729)
	\$ (3,534,350)	\$ 1,051,854

In addition to the non-cash items noted in Note 13, we also had the following non-cash items that were excluded from the Statements of Cash Flows for the six months ended March 31, 2022:

- \$2,924,880 non-cash share offering costs and \$453,102 accounts payables as part of the net proceeds settlement at the closing of the U.S. IPO and Canadian Offering;
- 250,000 warrants exercised in connection with the GhostStep<sup>TM</sup> acquisition in June 2020; and
- \$528,207 of shares issued for vested RSUs and PSUs.

The following is a summary of non-cash items that were excluded from the Statements of Cash Flows for the six months ended March 31, 2022:

- \$19,000 debt settlement via common shares;
- \$61,136 fair value of warrants exercised and transferred to share capital from warrants; and
- \$125,000 for 250,000 warrants exercised in connection with the GhostStep<sup>TM</sup> acquisition in June 2020.

#### 19. Commitments and contingencies

Except as noted below, there was no material change to the commitments and contingencies as disclosed in Note 26 of the audited consolidated financial statements for the year ended September 30, 2022.

In March 2023, we committed to signing a three-year lease agreement in Guelph, Canada for our non-lethal operations. The lease will begin August 1, 2023 and expire on June 30, 2026, for a total commitment of \$208,285.

Notes to Unaudited Condensed Consolidated Interim Financial Statements Three and six months ended March 31, 2023, and 2022 (Expressed in Canadian dollars, except share amounts)

# 20. Segmented information

Our Executive Chairman has been identified as the chief operating decision maker. Our Executive Chairman evaluates the performance of KWESST and allocates resources based on the information provided by our internal management system at a consolidated level. We have determined that we have only one operating segment.

At March 31, 2023, all of our property and equipment are located in Canada, including the right-of-use assets.